SEEBRI NEOHALER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Seebri Neohaler, and what generic alternatives are available?
Seebri Neohaler is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has ninety-nine patent family members in thirty-two countries.
The generic ingredient in SEEBRI NEOHALER is glycopyrrolate. There are seventeen drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri Neohaler
A generic version of SEEBRI NEOHALER was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SEEBRI NEOHALER?
- What are the global sales for SEEBRI NEOHALER?
- What is Average Wholesale Price for SEEBRI NEOHALER?
Summary for SEEBRI NEOHALER
| International Patents: | 99 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for SEEBRI NEOHALER |
| What excipients (inactive ingredients) are in SEEBRI NEOHALER? | SEEBRI NEOHALER excipients list |
| DailyMed Link: | SEEBRI NEOHALER at DailyMed |
US Patents and Regulatory Information for SEEBRI NEOHALER
SEEBRI NEOHALER is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | 8,479,730 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | 8,182,838 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SEEBRI NEOHALER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 7,229,607 | ⤷ Start Trial |
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,956,661 | ⤷ Start Trial |
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,029,768 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SEEBRI NEOHALER
See the table below for patents covering SEEBRI NEOHALER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 256450 | ⤷ Start Trial | |
| Austria | 355822 | ⤷ Start Trial | |
| Austria | 526946 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEEBRI NEOHALER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1267866 | C300583 | Netherlands | ⤷ Start Trial | PRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928 |
| 1267866 | CA 2013 00015 | Denmark | ⤷ Start Trial | |
| 1267866 | 92166 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch